Trial Profile

A Phase I Trial of VP02 for Treating Idiopathic Pulmonary Fibrosis (IPF) and Related Cough

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 04 Jul 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Thalidomide (Primary)
Indications Cough; Idiopathic pulmonary fibrosis
Focus Adverse reactions
Sponsors Vicore Pharma

Most Recent Events

14 Feb 2020 New trial record
11 Feb 2020 According to a Nanologica media release, Vicore Pharma is now in the process of conducting toxicological studies after which they plan to start this phase I study with the drug candidate using Nanologicas technology (VP02).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com